Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chagas Disease - Pipeline Review, H2 2016, provides an overview of the Chagas Disease (Infectious Disease) pipeline landscape.

Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting and swollen glands. Treatment includes antiparasitic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chagas Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chagas Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 2 and 6 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 16 and 4 molecules, respectively for Chagas Disease.

Chagas Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chagas Disease (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Chagas Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chagas Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chagas Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chagas Disease (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chagas Disease (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chagas Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Chagas Disease (American Trypanosomiasis) Overview 9
Therapeutics Development 10
Pipeline Products for Chagas Disease (American Trypanosomiasis) - Overview 10
Pipeline Products for Chagas Disease (American Trypanosomiasis) - Comparative Analysis 11
Chagas Disease (American Trypanosomiasis) - Therapeutics under Development by Companies 12
Chagas Disease (American Trypanosomiasis) - Therapeutics under Investigation by Universities/Institutes 13
Chagas Disease (American Trypanosomiasis) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Chagas Disease (American Trypanosomiasis) - Products under Development by Companies 17
Chagas Disease (American Trypanosomiasis) - Products under Investigation by Universities/Institutes 18
Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development 19
Bayer AG 19
Eisai Co., Ltd. 20
GlaxoSmithKline Plc 21
Grupo Praxis Pharmaceutical SA 22
KaloBios Pharmaceuticals, Inc. 23
Merck & Co., Inc. 24
Novartis AG 25
Sanofi 26
Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
benznidazol - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
benznidazole - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
chagas disease (bivalent) vaccine - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
chagas disease vaccine - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
chagas disease vaccine - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Chagas disease vaccine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Cz-007 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Cz-008 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
EPLBS-1246 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
EPLBS-967 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
fexinidazole - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
fosravuconazole - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
GNF-6702 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
K-777 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
NEU-321 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
nifurtimox - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
nifurtimox SR - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
posaconazole - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
SAR-114137 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecule to Inhibit Cruzipain for Chagas Disease - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Small Molecules for Chagas Disease - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Small Molecules for Chagas Disease - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Small Molecules for Chagas Disease - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Small Molecules for Chagas Disease - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Small Molecules for Chagas Disease - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Small Molecules for Infectious Diseases - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Small Molecules for Infectious Diseases - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Small Molecules for Protozoal Infections - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Small Molecules to Inhibit Proline Racemase for Chagas Disease - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
VNI - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Chagas Disease (American Trypanosomiasis) - Dormant Projects 72
Chagas Disease (American Trypanosomiasis) - Discontinued Products 73
Chagas Disease (American Trypanosomiasis) - Product Development Milestones 74
Featured News & Press Releases 74
Apr 11, 2016: KaloBios Announces New Product Pricing Model 74
Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease 74
May 07, 2015: UTMB researchers devise vaccine that provides long-term protection against Chagas disease 75
Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease 76
Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy 77
May 03, 2013: Funding boost for GSK's open innovation research into diseases affecting the developing world 78
Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease 79
Mar 12, 2012: DNDi Receives €2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease 80
Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 81
Disclaimer 82

List of Tables

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H2 2016 10
Number of Products under Development for Chagas Disease (American Trypanosomiasis) - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Chagas Disease (American Trypanosomiasis) - Pipeline by Bayer AG, H2 2016 19
Chagas Disease (American Trypanosomiasis) - Pipeline by Eisai Co., Ltd., H2 2016 20
Chagas Disease (American Trypanosomiasis) - Pipeline by GlaxoSmithKline Plc, H2 2016 21
Chagas Disease (American Trypanosomiasis) - Pipeline by Grupo Praxis Pharmaceutical SA, H2 2016 22
Chagas Disease (American Trypanosomiasis) - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2016 23
Chagas Disease (American Trypanosomiasis) - Pipeline by Merck & Co., Inc., H2 2016 24
Chagas Disease (American Trypanosomiasis) - Pipeline by Novartis AG, H2 2016 25
Chagas Disease (American Trypanosomiasis) - Pipeline by Sanofi, H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Chagas Disease (American Trypanosomiasis) - Dormant Projects, H2 2016 72
Chagas Disease (American Trypanosomiasis) - Discontinued Products, H2 2016 73